Skip Navigation

JNCI Journal of the National Cancer Institute 2005 97(14):1031; doi:10.1093/jnci/dji229
This Article
Right arrow Full Text Freely available
Right arrow FREE Full Text (PDF) Freely available
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Alert me to new issues of the journal
Right arrow Add to My Personal Archive
Right arrow Download to citation manager
Right arrow Request Permissions
Google Scholar
Right arrow Articles by Hayasaka, E.
Right arrow Articles by Zielinski, S. L.
Right arrow Search for Related Content
PubMed
Right arrow Articles by Hayasaka, E.
Right arrow Articles by Zielinski, S. L.
Social Bookmarking
Add to CiteULike   Add to Connotea   Add to Del.icio.us  
What's this?

© 2005 Oxford University Press

NEWS

In Brief

Elana Hayasaka, Sarah L. Zielinski

The first 10% of the full text of this article appears below.

NCI To Revamp Clinical Trials System in 2006

The National Cancer Institute's National Cancer Advisory Board has accepted a 5-year plan for implementation of 22 initiatives for revamping NCI's clinical trials system.

Last year, the Clinical Trials Working Group was charged with redesigning the NCI's clinical trials system to improve efficiency and speed research. The CTWG proposed several changes . . . [Full Text of this Article]

FDA, AstraZeneca Limit Distribution of Gefitinib

Bortezomib May Be More Effective, but More Toxic, for Multiple Myeloma


Add to CiteULike CiteULike   Add to Connotea Connotea   Add to Del.icio.us Del.icio.us    What's this?